Konkurrieren Explosion WeltrekordGuinnessBuch sotagliflozin type 2 diabetes Besucher desinfizieren Seeanemone
Sotagliflozin with Insulin therapy prevents DKA in young Type 1 Diabetics: Study
The inTandem 2 study: 52-week efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in adults with type 1 diabetes - Media Centre | EASD
SCORED/SOLOIST: Dual inhibitor provides benefits in type 2 diabetes and heart failure, CKD
Herzinsuffizienz | Sotagliflozin bei Diabetes mellitus Typ 2 und Herzinsuffizienz | springermedizin.de
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes | NEJM
Sotagliflozin reduces deaths, time spent in hospital for some patients with diabetes
Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/ 2 inhibitor - Pablo Lapuerta, Brian Zambrowicz, Paul Strumph, Arthur Sands, 2015
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM
JDRF-T1D Win: Zynquista Approved in Europe for Type 1 Diabetes
SCORED : Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk – My Endo Consult
Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives | Cardiovascular Diabetology | Full Text
Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives | Cardiovascular Diabetology | Full Text
Sotagliflozin for patients with type 2 diabetes: A systematic review and meta‐analysis - Avgerinos - 2022 - Diabetes, Obesity and Metabolism - Wiley Online Library
Sotagliflozin reduces hospitalizations and urgent visits for patients with diabetes and worsening heart failure | 2 Minute Medicine
Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, in overweight/obese patients with type 1 diabetes: addressing unmet needs as adjunct therapy to insulin - Media Centre | EASD
Postprandial glucose excursions with sotagliflozin in patients with... | Download Scientific Diagram
sotagliflozin
Summary of cardiovascular outcome trials with sodium-glucose... | Download Scientific Diagram
Sanofi and Lexicon collaborate on sotagliflozin
Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials | The BMJ